Timothy I. Still Appointed as President and CEO of Myoscience

Timothy I. Still Appointed as President and CEO of Myoscience

Myoscience, Inc. announced today the appointment of Timothy I. Still as its new President and Chief Executive Officer.

FREMONT, Calif. (PRWEB) October 01, 2018

Myoscience, Inc. announced today the appointment of Timothy I. Still as its new President and Chief Executive Officer. Mr. Still will also be joining the Company’s Board of Directors.

Mr. Still’s background includes over 28 years of experience in medical devices and diagnostics. He has extensive leadership experience in designing and implementing highly focused commercial and business development strategies within both small and large companies. Mr. Still has been directly responsible for building the commercial viability at many of his previous companies, four of which have been successfully acquired.

Most recently, Mr. Still was the Executive Chairman of Gold Standard Diagnostics. He served on the company’s Board for over four years; and subsequently took on a more active role resulting in the sale of the company to Eurofins in July of 2018. Prior appointments include CEO roles at Global Kinetics Corporation, Xagenic and Accumetrics. Mr. Still has also held executive positions at HemoSense, Cholestech Corporation and Boehringer Mannheim Corporation. He received a B.S. degree (with Honors) in Biological Sciences from the University of California at Davis, and an MBA (Deans Scholar) in Marketing and Entrepreneurship from the University of Southern California.

“I am honored to be given the opportunity to lead Myoscience at this exciting time in the company’s history. With its vast market opportunity, patented technology, increasing commercial adoption and product development pathway, Myoscience is positioned for tremendous success” said Mr. Still.

Brian Farley, Chairman of the Board at Myoscience commented, “We are very pleased to welcome an executive with the leadership and track record of Timothy Still. With his experience in the commercialization of innovative medical technologies, we believe that Tim’s strong operational and business development skills will be instrumental at helping Myoscience successfully execute our strategy of delivering our iovera® pain management solution for the millions of patients with painful conditions, particularly those with osteoarthritis of the knee or who undergo knee replacement surgery.

The board would also like to thank Edward Kleinhans for his leadership during the last five months as Interim Chief Executive Officer at Myoscience.

For additional information, please visit https://iovera.com or email us directly at mediarelations@myoscience.com.

ABOUT MYOSCIENCE
Silicon Valley, California-based Myoscience is a privately-held medical device company committed to making its platform technology, the iovera° system, the standard of care for the treatment of peripheral nerves. The iovera° treatment is powered by a patented miniaturization of traditional cryotherapy. The ioveraº system is 510k cleared in the U.S. for the blocking of pain, the relief of pain and symptoms associated with osteoarthritis of the knee for up to 90 days and general surgical use. For more information, please visit http://www.iovera.com.

© 2018 Myoscience. All rights reserved. iovera° is a trademark of Myoscience. MKT-0521 REV A